Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Core Viewpoint - Rallybio Corporation is experiencing a significant increase in share price following the announcement of a merger agreement with Candid Therapeutics Inc, which is expected to enhance its portfolio of T-cell engager therapeutics for autoimmune diseases [1][4] Merger Details - The merger will involve Rallybio acquiring Candid, which has raised over $505 million in financing from prominent healthcare institutional investors [2] - The combined company is projected to have pro-forma cash of approximately $700 million, providing a robust financial foundation to support operations through 2030 and advance multiple clinical milestones, including Phase 2 studies for T-cell engager programs [2] - The transaction is expected to close in mid-2026, subject to stockholder approval and regulatory conditions [3] - Post-merger, Rallybio equityholders will own about 3.65% of the combined entity, while Candid equityholders will hold approximately 96.35% [3] - The new entity will operate under the name Candid Therapeutics and trade on Nasdaq with the ticker symbol "CDRX" [3] Market Context - The broader market saw declines, with the Nasdaq down 1.40% and the S&P 500 falling 1.07%, indicating that Rallybio's stock gains are driven by company-specific news rather than overall market trends [4] - Rallybio shares rose by 29.05% to $9.73, reaching a new 52-week high according to Benzinga Pro data [4]